Sponsors (7)
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Reorganizes the current National Institute of Allergy and Infectious Diseases (NIAID) into three separate institutes focused on allergic diseases, infectious diseases, and immunologic diseases. It terminates the single NIAID Director on enactment, places temporary oversight with the NIH Director, and sets five-year presidential appointment terms (with one reappointment) for the three new institute directors. The law makes many conforming changes to the Public Health Service Act and transfers statutory authorities to the new institutes, but it does not provide new appropriations or dollar amounts.
The bill aims to improve research focus and administrative clarity by splitting and statutorily defining institutes and leadership terms, but risks costly transitions, service gaps, and fragmentation of integrated research if funding, staffing, and coordination aren't properly managed.
Researchers, hospitals, and public-health communities will gain institutes with narrower, disease-specific missions, enabling more focused research and programmatic attention on infectious, immunologic, and allergic diseases.
Federal programs will have clearer statutory authorities and transition rules, which could reduce administrative overlap and improve program clarity across disease areas.
Institute leadership will operate under fixed 5-year presidential terms, increasing leadership stability and predictability for long-term research planning.
Taxpayers, hospitals, and research communities could face administrative costs or gaps in services if NIAID is split without new appropriations or proper reallocation of funding and staff.
Patients with conditions at the intersection of immunity, infection, and allergy and the researchers who study them may see fragmented or less-coordinated research if the Allergic Diseases institute's statutory duties are narrowed.
Federal employees and research leaders could face disruptive leadership turnover because the existing NIAID Director would be terminated immediately, creating uncertainty during the transition to new institute directors.
Introduced February 21, 2025 by Charles Roy · Last progress February 21, 2025